title: Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival.
abstract: Human thioredoxin is a putative oncogene that may confer both a growth and survival advantage to tumor cells. Overexpressed thioredoxin mRNA has been found in both primary human lung and colorectal cancers. To determine the intratumor distribution and amount of thioredoxin protein in human primary carcinomas, we developed an immunohistochemical assay for thioredoxin in paraffin-embedded tissue. We then studied 10 patients with primary high-risk gastric carcinoma. To further relate thioredoxin protein overexpression to cell death and survival, we used a paraffin-based in situ end-labeling (ISEL) assay. To delineate proliferation, we used the nuclear proliferation antigen detected by Ki-67. In this survey, we found that thioredoxin was localized to tumor cells and overexpressed compared with normal gastric mucosa in 8 of 10 gastric carcinomas. The thioredoxin was found at high levels in 5 of the 8 overexpressing carcinomas. The overexpression of thioredoxin was typically found in both a nuclear and cytoplasmic location in the neoplastic cells. There was a significant positive correlation (P = .0061) with cancer cell proliferation measured by Ki-67. There was a significant negative correlation (P = .0001) with DNA damage measured by the ISEL assay, suggesting decreased apoptosis and increased carcinoma cell survival. Thus, human primary gastric tumors that are highly expressive of thioredoxin have both a higher proliferative rate and a higher survival rate than tumors that do not express thioredoxin. With these newly developed assays in hand, it is now feasible to question whether this thioredoxin-related combined growth and survival advantage translates into poor clinical outcome.
authors.affiliation: University of Arizona Cancer Center and Department of Pathology, Tucson, USA.
authors.forename: T M
authors.initials: TM
authors.lastname: Grogan
authors.forename: C
authors.initials: C
authors.lastname: Fenoglio-Prieser
authors.forename: R
authors.initials: R
authors.lastname: Zeheb
authors.forename: W
authors.initials: W
authors.lastname: Bellamy
authors.forename: Y
authors.initials: Y
authors.lastname: Frutiger
authors.forename: E
authors.initials: E
authors.lastname: Vela
authors.forename: G
authors.initials: G
authors.lastname: Stemmerman
authors.forename: J
authors.initials: J
authors.lastname: Macdonald
authors.forename: L
authors.initials: L
authors.lastname: Richter
authors.forename: A
authors.initials: A
authors.lastname: Gallegos
authors.forename: G
authors.initials: G
authors.lastname: Powis
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D017209:Apoptosis; D002455:Cell Division; D002470:Cell Survival; D053938:DNA Fragmentation; D004273:DNA, Neoplasm / Q000032:analysis; D006801:Humans; D007124:Immunoenzyme Techniques; D020287:In Situ Nick-End Labeling; D019394:Ki-67 Antigen / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D013879:Thioredoxins / Q000378:metabolism*
chemical_list: D004273:DNA, Neoplasm; D019394:Ki-67 Antigen; D011518:Proto-Oncogene Proteins; D013879:Thioredoxins